Bergen County's Luxury Housing Market Is Increasingly Concentrated Across $3M-$10M+ Price Tiers, NJMLS Data Shows NJ Proper ranks #1 in Bergen County across every major high-end residential segment from $4M+ through $10M+, with expanding leadership at the $3M+ level GlobeNewswire January 29, 2026 TENAFLY, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) — Analysis of New Jersey […]
(OTCQB:CSDX),(OTC US:CSDX), CHEYENNE, Wyo., Jan. 29, 2026 (GLOBE NEWSWIRE) — CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with Emirate Wet Wipes LLC that accelerate the Company's transition into full commercial production ahead of the global launch of MEDUSA SDP, its next-generation medical-grade
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products GlobeNewswire January 29, 2026 CHEYENNE, Wyo., Jan. 29, 2026 (GLOBE NEWSWIRE) — CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with Emirate Wet Wipes LLC that
Philadelphia, Pennsylvania–(Newsfile Corp. – January 29, 2026) – National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22,
blueharbor bank (the “Bank”) today reported earnings for the fourth quarter of 2025. Fourth Quarter 2025 Highlights — Exceeded $600 million in assets. — Return on average assets (ROA) of 2.18% — Return on average equity (ROE) of 19.84% — Net interest margin remained high at 4.30% — Efficiency ratio of 35.66% — Loan growth
(NASDAQ:PALI), Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026
(NASDAQ:ITRI), LIBERTY LAKE, Wash., Jan. 29, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is showcasing the latest advancements with its Grid Edge Intelligence portfolio as well as its newly formed Resiliency Solutions segment at DTECH 2026 in San Diego, Calif.,
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors. After going to medical school at the University of Maryland School of Medicine and doing residency at the University of Massachusetts Medical Center, Dr. Houff
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board GlobeNewswire January 29, 2026 Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward
Itron to Showcase Advancements in Grid Edge Intelligence and Resiliency at DTECH 2026 End-to-End Solutions Address Grid Complexity, Rising Energy Demand and Reliability Challenges GlobeNewswire January 29, 2026 LIBERTY LAKE, Wash., Jan. 29, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water,